



An ITEA Smart health project

SIGNET



Reducing complexity in clinical diagnosis and treatment pathways

Project summary

The aim of SIGNET is to realize the North Star of replacing complex medical workflows and procedures by single-episode personalized, dose-adaptive, precision Magnetic Resonance guided treatments and interventions, improving patient comfort, safety, treatment outcome, and economic viability.



Canada
imeka
MODUS QA

Consortium

Project duration

November 2021 - January 2025

United States
imricor

The Netherlands
Amsterdam UMC
BRAIN SCIENCE TOOLS
LifeTec Group
Machnet Medical Robotics
PHILIPS
UMC Utrecht



Spain
ADAS3D MEDICAL
GALGO MEDICAL

Expected key results / USPs

- Single unified interface for the treatment device manufacturers to integrate with the MR system across neurology, cardiology & oncology domains.
- Better AI driven image quality with up to 60% faster speed.
- SIGNET innovations will position European MR guided treatment industry to more effectively compete with the ventures from the rest of the world, and allow treatment device manufacturers a quicker path to clinical evaluation and market adoption.
- Expected direct annual societal gain of over EUR 1 billion by the end of this decade, through these innovations.

Project website

Project LinkedIn



SCAN ME

<https://signetproject.com/>



SCAN ME

<https://www.linkedin.com/company/itea-signet/>

SIGNET technology building blocks



This ITEA project is supported by:



Contact

Saurav Kumar Baidya
Philips - The Netherlands
E: saurav.baidya@philips.com T: +31 6 3809 9296

